Objective: Contrast-enhanced ultrasound (CEUS) imaging is a powerful noninvasive modality offering numerous potential diagnostic and therapeutic applications in vascular medicine. CEUS imaging uses microbubble contrast agents composed of an encapsulating shell surrounding a gaseous core. These microbubbles act as nearly perfect intravascular reflectors of ultrasound energy and may be used to enhance the overall contrast and quality of ultrasound images. The purpose of this narrative review is to survey the current literature regarding CEUS imaging and discuss its diagnostic and therapeutic roles in current vascular and selected nonvascular applications.
Contrast-enhanced ultrasound (CEUS) imaging is an emerging, noninvasive imaging modality that offers promise toward diagnostic and therapeutic applications in vascular medicine. CEUS uses microbubbles, which are contrast agents with thin and relatively permeable shells containing high-molecular-weight gases that do not readily diffuse or dissolve within the bloodstream. Microbubbles have a high degree of echogenicity and act as nearly perfect intravascular reflectors of acoustic ultrasound energy without local disruption. Because blood and surrounding tissues are similar in echogenicity, the addition of microbubble contrast agents may be used to enhance the overall contrast and quality of ultrasound images. 1, 2 In 1968, Gramiak and Shah were credited as the first group to observe contrast effects in M-mode echocardiography. 1 They described the phenomenon by which rapid intracardiac saline injections produced bubbles that enhanced delineation of aortic blood flow. In the late 1970s, Bommer et al were the first to describe the development of miniscule yet stable microbubbles capable of traversing the pulmonary system without destruction. 1 This microbubble technology was subsequently fine tuned for direct in vivo visualization of intact mammalian vessels as small as capillaries. The earliest clinical application of microbubbles was to identify myocardial perfusion patterns with contrast echocardiography. 1, 2 Since the advent of United States Food and Drug Administration-approved commercially available intravenous ultrasound contrast agents, the clinical utility of microbubble technology to assess dynamic spatial and temporal heterogeneity of tissue microvasculature has grown exponentially. This review presents the current vascular applications of CEUS imaging and discusses its emerging diagnostic and therapeutic roles.
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OVERVIEW OF CEUS
Physics background. Microbubbles of air commonly occur within all living organisms; however, their existence is extremely short-lived due to significant external compressive forces. 1 Microbubble contrast agents, by comparison, are classically composed of an encapsulating shell surrounding a gas core. The shell is typically composed of albumin, galactose, lipids, or polymers and functions to increase the circulation time and durability of the microbubble agent while also reducing the rate of release of the gaseous core. 1 Hydrophilic shell materials are taken up by the immune system more easily, leading to reduced agent circulation time. The elasticity of the shell contributes to the durability of the agent, and shells that are more elastic able to withstand higher levels of acoustic energy before rupture. 3 The composition of the gaseous core contributes to the overall stability and echogenicity of the microbubble. Gases with higher molecular weight and lower blood solubility require more time to diffuse through the shell, leading to increased circulation time of the agent. Firstgeneration contrast enhancement used CO 2 bubbles as a contrast medium, but today this has been wholly supplanted by the use of sulfur hexafluoride and perfluorocarbons. 1, 3 A list of commercially available contrast agents is provided in the Table. Ultrasound transducers emit sound waves leading to rapid variations in acoustic pressure. Microbubbles in the bloodstream undergo resonant volumetric oscillations in response to this variation in pressure, leading to asymmetric changes in microbubble diameter. These bubbles stiffen when compressed during the highpressure portion of a sound wave, leading to smaller changes in size than is seen during the low compression (low stiffness) phase. The asymmetric changes in microbubble size lead to the reflection of sound waves with strong nonlinear components in multiples of the transmitting frequency, in contrast to the waves with linear components reflected by tissue and tissue motion. 2 The strength of the nonlinear components depends on the mechanical index (MI) of the sound field, a standardized estimate of peak acoustic intensity (peak negative pressure divided by the square root of transmission frequency). Early ultrasound machines used acoustic energy with a high MI (>0.2) for imaging. Advantages of a high-MI method include a high signal-to-noise ratio and increased sensitivity for microbubbles, allowing for the assessment of myocardial perfusion.
1,2 However, it was soon discovered that high-MI perfusion imaging disrupts microbubble shells leading to rapid elimination of the contrast agent, which prevented the simultaneous assessment of wall motion. Conversely, newer machines using low-MI imaging were still able to detect microbubbles without disrupting them, thereby allowing for both real-time imaging and assessment of perfusion. 2 The mechanical index also reflects the likelihood of adverse mechanical (nonthermal) biologic effects on nearby tissues. The interaction of acoustic ultrasound energy with microbubble contrast agents in the vasculature leads to rapid changes in microbubble volume in a process termed cavitation. These changes in microbubble size may be accompanied by increases in pressure and temperature within the contrast agent, leading to mechanical stress on surrounding tissues, fluid microjet formation, or the generation of free radicals. Cavitation involving microbubbles (microcavitation) has been recognized as the most likely mechanism for the nonthermal bioeffects of diagnostic ultrasound imaging, including microvascular rupture, petechiae, and inflammatory cell infiltration. The propensity for microcavitation to occur is related to the transmitting frequency of the ultrasound probe, with cavitation less likely to occur at higher transducer frequencies (low MI). As such, in the United States, the Food and Drug Administration limits ultrasound machine output to an MI of at most 1.9 to avoid inadvertent bioeffects. 4, 5 Administration of 0.1 to 5.0 mL of an aqueous solution containing ultrasound contrast agents (w10 9 bubbles/ mL) is typically required for enhancement of the blood pool. Microbubble contrast agents may be administered intravenously as a bolus or as an infusion at a rate of #1 mL/min, followed by a flush of 5 to 10 mL of 0.9% saline solution. A repeat bolus injection can be added if needed for additional imaging. Once a steady amount of enhancement is obtained, a series of acoustic pulses are applied, which disrupt the bubbles in the ultrasound frame. Subsequently, new bubbles re-enter the frame from adjacent vessels in which the rate of replenishment is directly proportional to the regional blood flow rate. 2, 5 Consequently, areas with a perfusion defect appear less bright than hyperperfused areas in the ultrasound frame for a given time after bubble disruption. Thus, serial measurements of the amount of opacification, or "brightness," as a function of time after microbubble disruption can allow for estimation of the velocity and relative volume of blood flow in the imaging frame. 5 Mathematical models may be used to estimate blood flow parameters after the administration of microbubble contrast agents. A time-intensity curve (TIC) may be created to reflect the intravascular transit of the contrast agent. TICs reflect the average intensity in a region of interest, measured in absolute intensity units, over time in seconds. Plotting TIC in a given frame allows for quantification of various parameters, including time to peak, peak intensity, area under the curve, wash-in and wash-out time, and mean transit time. Some of these parameters, such as peak intensity and area under the curve, reflect local blood volume in the region of interest, whereas, other parameters (time to peak intensity, wash-in/wash-out time) are more reflective of blood flow.
5 With these calculations, CEUS imaging can noninvasively quantify the spatial and temporal characteristics of blood flow and volumes within the macrovasculature and microvasculature. Molecular background. Much recent research has focused on extracardiac vascular applications of CEUS imaging, namely to identify and quantify neovascularization within atherosclerotic plaques, enhance vascular structures, and quantify tissue perfusion. [6] [7] [8] [9] [10] Plaque neovascularization is formed by a network of capillaries originating from adventitial vasa vasorum rather than the luminal surface. As an atherosclerotic plaque grows, the reduced oxygen diffusion to the arterial wall leads to reactive thickening of the intima-media complex. This increased intimal media thickness (IMT) further restricts diffusion, leading to the compensatory release of angiogenic factors and subsequent overgrowth of the vasa vasorum. 6, 11 A postmortem study comparing wall samples of iliac, carotid, and renal arteries between patients who suffered from cardiovascular events and those who did not revealed that the former had a higher intimal macrophage content and denser network of vasa vasorum uniformly present in different arterial beds. 7 Moreover, vasa vasorum density, and thus intraplaque neovascularization, is considered a predictor of vulnerable lesions associated with plaque rupture and occlusive cardiovascular events. 7, 12 Using immunohistochemical markers of vascularity, multiple studies have found a correlation between neovascularization seen on CEUS imaging and neovascularization seen histologically using cluster of differentiation 31-and 34-stained specimens of atherosclerotic lesions, including those obtained via carotid endarterectomy (CEA). 7, 12 Thus, CEUS imaging can accurately assess neovascularization and better illuminate vascular abnormalities, which may be used for risk stratification of patients with atherosclerotic disease.
APPLICATIONS FOR EXTRACRANIAL CAROTID OCCLUSIVE DISEASE
To date, the prediction of cerebrovascular accident (CVA) risk in patients with carotid occlusive disease predominantly depends on the presence of neurologic symptoms and the degree of stenosis, with CEA indicated for select patients with a high degree of stenosis. CEUS imaging may further aid in determining the need for CEA in patients, regardless of the degree of stenosis, based on assessment of plaque morphology and vulnerability. CEUS imaging allows for a more accurate measurement of the degree of stenosis and strongly correlates with conventional angiography and magnetic resonance angiography. 13 In addition, CEUS reduces the visualization of intrastenotic flow artifacts, thus improving measurements of length of stenosis compared with color Doppler ultrasound imaging.
14 CEUS imaging can also reveal irregularities previously undetected by conventional ultrasound imaging such as ulcers, hypoechoic plaques, and dissections.
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Hypoxia-induced neovascularization also plays a role in carotid plaque progression, which can be directly visualized by CEUS imaging. 1, 6, 12 As mentioned above, the progression of carotid atherosclerosis and reactive increase in IMT lead to the compensatory release of angiogenic factors and growth of the vasa vasorum. These vessels lacking pericytes leak, causing increased plaque volume and instability, which can become symptomatic and acutely manifest itself with cerebrovascular events.
Indeed, increased IMT itself has been found to be directly correlated with the increased incidence of CVA, myocardial infarction, increased left ventricular mass, and peripheral vascular disease. Macioch et al 15 discovered
that CEUS imaging enhanced visualization of the intima-luminal border, allowing for more accurate IMT measurements than conventional ultrasound imaging. In addition, the neovascularization visualized by CEUS imaging correlates with the degree of carotid stenosis 17 In fact, one study used CEUS imaging to visualize regression of vasa vasorum in a 53-year-old diabetic patient after induction of statin therapy, reflecting another potential benefit of CEUS imaging as a modality to monitor response to medical therapy. 11 Although CEUS imaging appears to be a promising diagnostic modality for assessing intraplaque neovascularization, future steps required before widespread use include multicenter studies of sufficient sample size with a broad spectrum of patients and standardization of quantitative analysis and visual grading classification to reduce technical heterogeneity. 18 
APPLICATIONS FOR ABDOMINAL AORTIC ANEURYSMS
CEUS imaging has many future implications for the diagnosis and management of prerupture abdominal aortic aneurysms (AAAs), ruptured AAAs, and endoleaks after endovascular aneurysm repair (EVAR). Compared with conventional ultrasound imaging, CEUS imaging improves visualization of aortic lumen perfusion, main branching arteries, and thrombi on the aortic wall with good correlation with computed tomography angiography (CTA). 8 CEUS imaging may thus be a viable alternative to CTA, especially when an existing contrast allergy, radiation exposure, or cost is a concern. CEUS imaging also resolves some of the limitations of conventional ultrasound imaging for ruptured AAA patients by enhancing visualization of the aneurysmal wall and real-time leakage of extravascular fluid as well as identification of retroperitoneal hematomas without causing significant delays in surgery. 19 Future directions may include the use of CEUS imaging to identify and quantify neovascularization within the aortic wall and overlying thrombus to correlate it with growth rates and adverse clinical outcomes. 20 The intraoperative use of CEUS imaging has been suggested as a means of reducing nephrotoxic contrast in patients with impaired renal function, replacing CO 2 angiography and its significant limitations. 21 It was recently suggested that intraoperative three-dimensional (3D) CEUS imaging can accurately identify the renal arteries and endoleaks immediately after stent graft deployment. Such imaging may detect and characterize endoleaks not seen on uniplanar angiography and has advantages over 2D CEUS imaging in inflow vessel identification and image manipulation. The application uses magnetic field emitters to precisely position the ultrasound probe and interrogate an endograft from any angle within the aneurysm. Simultaneous multiplanar data acquisition allows for rapid image acquisition and subsequent high-resolution reconstruction of the target vessel.
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Post-EVAR endoleaks result from persistent blood flow into the aneurysmal sac outside or through the stent graft, which may lead to progressive aneurysmal enlargement and secondary rupture. They are the most frequent complication after EVAR, occurring in 10% to 45% of patients. One meta-analysis with 285 combined patients revealed a pooled sensitivity of 98% and specificity of 88% for CEUS imaging in detecting an endoleak. 23 Compared with conventional ultrasound imaging, CEUS imaging provides good sensitivity even in technically difficult conditions caused by patient body habitus and presence of bowel gas. 24 Furthermore, studies have shown that CEUS imaging is superior to CTA in detecting the presence and type of endoleaks. 24, 25 One study of 20 patients with aortic stent grafts revealed that CEUS was able to identify and differentiate between type I and type II leaks for all eight endoleaks identified by CTA. 24 CTA, however, was unable to identify the source of endoleak for three of these eight patients, possibly as a result of metallic artifact localized to that region of the graft. Moreover, CEUS imaging identified two additional endoleaks that were previously undetected by CTA. 24 The second study similarly demonstrated that CEUS imaging detected endoleaks in 10 patients with unexplained post-EVAR aneurysmal enlargement that went undetected by CTA possibly due to slow flow, with the type of endoleak identified in eight of these patients. 25 Thus, CEUS imaging is an ideal adjunctive surveillance modality when CTA or conventional ultrasound imaging are nondiagnostic, contraindicated, or unable to identify the type of endoleak. Despite these advantages, CEUS imaging has not yet achieved widespread use for post-EVAR surveillance. This is partially because CEUS technology is largely unavailable in the United States, with the exception of select academic centers involved in ongoing research. Moreover, the learning curve for technicians to perform these studies is steep and requires familiarity with the required setting on the ultrasound unit as well as the ability to differentiate true endoleaks from artifact. Additional limitations to the use of CEUS imaging are similar to those of conventional ultrasound imaging such as operator dependence and that image quality can be impaired by body habitus or bowel gas, or both. 26 The use of CEUS imaging is not without risk of complications. The most important possible adverse effect associated with use of an ultrasound contrast agent is anaphylactic reaction, which is reported to occur in one of 100,000 cases. Other complications include those inherent to vascular puncture, including iatrogenic pseudoaneurysm, arteriovenous fistula, dissection, and hematoma formation, which are all exceedingly rare with venipuncture. 27 Nonetheless, the combination of cost savings estimated at $1595 per patient per year, lack of nephrotoxic contrast media or radiation exposure, and reproducibility with diagnostic accuracy equal to or greater than the current gold standard suggest CEUS imaging may replace routine CTA as the first-line post-EVAR surveillance modality. 28 Future applications may use 3D CEUS imaging, which uses positional information from magnetic field emitters and tracking sensors to combine all ultrasound reflections into a high-definition 3D image, to more confidently detect the source and outflow of endoleaks compared with CEUS imaging, CTA, and conventional angiography. 29 
APPLICATIONS FOR AORTIC DISSECTIONS
Acute aortic dissection presents nonspecifically with tearing chest, abdominal, or back pain, or all three, asymmetric pulses and pressures, and signs of end-organ ischemia. Ideally, patients with dissections should be diagnosed early in the emergency department by conventional ultrasound imaging before CTA is even performed. However, conventional ultrasound imaging is usually not sensitive or specific enough for a definitive diagnosis. Contrast-enhanced transthoracic echocardiography (TTE) is superior to conventional ultrasound imaging in delineating true and false lumens by visualizing delayed flow and less opacity in the false lumen compared with the true lumen. 9, 30 In addition, contrast-enhanced TTE allows more prominent visualization of the intimal flap, entry and re-entry points, very small dissection membranes, and extension of the dissection into major aortic branches. 2, 30 Contrastenhanced transesophageal echocardiography (TEE) can also be used to eliminate the linear artifacts from reverberations of native structures that are often mistaken for ascending dissection flaps, preventing inappropriate surgical referral. imaging has a 97% sensitivity compared with multislice CT in the detection of acute aortic dissection. Therefore, CEUS imaging may represent a promising alternative imaging technique in patients whose condition does not allow examination by CTA. In the future with wider adoption of the technology and proper training on imaging and interpretation, the use of CEUS imaging in the emergency department may expedite the identification of patients with dissections who require emergency surgery even before a CTA is performed, thereby sparing the patient from nephrotoxic contrast, radiation, costs, and saving precious time.
APPLICATIONS FOR PERIPHERAL ARTERIAL DISEASE
Plotting time intensity curves after microbubble injection and subsequent bubble destruction allows for quick, noninvasive analysis of real-time skeletal muscle perfusion of the lower extremity. Duerschmied et al 31 used CEUS imaging to compare TICs of patients with peripheral arterial disease (PAD) and healthy controls. In their study, an intravenous bolus of the SonoVue (Bracco Diagnostics, Milan, Italy) contrast agent was administered to patients through an antecubital vein, and its appearance in the calf muscle was evaluated. The time to reach peak intensity in the calf was significantly longer in PAD patients than in controls, reflecting decreased skeletal muscle perfusion. Time to peak was also longer in patients with more advanced PAD stages and those with poor collateralization. 31 Another study selectively analyzed TICs at a small artery, muscle tissue, and vein in the calf muscle of patients with late diabetic syndrome (diabetes complicated by neuropathy, nephropathy, retinopathy, or diabetic foot syndrome), patients with PAD, and healthy controls. 32 The significantly longer contrast transit time from artery to vein observed in diabetic patients relative to PAD patients and healthy controls demonstrated and quantified impaired microcirculation in these diabetic patients. Thus, CEUS imaging may be a valuable alternative or adjunct to standard noninvasive tests, including ankle-brachial indices and pulse volume recording, for quantifying and monitoring peripheral arterial circulation. 33 More recently, Thomas et al 10 analyzed TICs of PAD patients, young controls, and elderly controls during postocclusive reactive hyperemia, which was induced using an automated cuff occlusion system. Although time to peak was twice as long in elderly controls and PAD patients, repeat test reliability was low. Interestingly, the area under the curve, which reflects total blood volume across 30 seconds of reperfusion, was larger in PAD patients than in elderly controls, reflecting the significant effect of age on lower extremity reperfusion.
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CEUS imaging shows promise for becoming a diagnostic tool for measuring an individual's muscle perfusion but requires normalized data and must become more standardized with reproducible results to be accepted as part of clinical practice.
MISCELLANEOUS DIAGNOSTIC APPLICATIONS
Cardiac applications. In addition to its role with vascular pathology, CEUS imaging also holds promise in enhancing diagnostic capability within the realm of cardiac disease. Although most prior contrast agents, such as dyes, chemicals, and radioactive isotopes, proved unhelpful with standard echocardiographic imaging, the evolution of microscopic gas-filled particles stable enough to pass through the pulmonary circulation to the cardiac chambers and myocardium has overcome many of the challenges encountered with such imaging techniques. TTE has many well-known limitations, especially in patients with a suboptimal acoustic window secondary to obesity, chronic obstructive pulmonary disease, congestive heart failure, chest deformities, or previous cardiothoracic surgery. 34 These limitations can result in incomplete visualization of the cardiac segments and poor image quality, rendering the examination nondiagnostic. The use of microbubble contrast agents has led to adequate opacification of the left ventricular cavity, improved assessment of regional wall motion, and clearer delineation of the endocardial borders during both rest and stress testing. 35 The OPTIMIZE cross-over study was the first to directly evaluate the effect of the addition of a contrast agent in dobutamine stress echocardiography (DSE). An analysis of 101 patients who underwent DSE, both with and without the Definity (Lantheus Medical Imaging, Inc, North Billerica, Mass) contrast agent, demonstrated that the addition of the contrast agent significantly improved the percentage of endocardial segments visualized at baseline and at peak stress (P < .001). 35 Moreover, the beneficial effect of the contrast agent on DSE diagnostic accuracy was highest in cases where unenhanced imaging failed to reveal multiple endocardial segments and thus confidence in interpretation was low. This improved diagnostic accuracy was attributed to both improved visualization of the endocardial border and improved sensitivity and specificity of detecting wall movement abnormalities. Obtaining a conclusive diagnosis with contrast echocardiography stress testing can minimize or preclude the need for further testing for diagnosing myocardial ischemia, including invasive procedures, thereby providing tremendous cost savings. 35 Optimal endocardial visualization is also necessary for accurate assessment of global and regional left ventricular functions, including the estimation of the left ventricular ejection fraction (EF). The use of microbubble contrast agents has been shown to improve the accuracy and reproducibility of echocardiography in the assessment of the EF compared with the noncontrast studies. 36 Fukuda et al 36 examined the effect of contrast echocardiography in 46 patients with coronary artery disease. They demonstrated that contrast echocardiography with the addition of microbubbles led to improved feasibility, accuracy, and reproducibility of automated measurements of left ventricular volume and EF compared with noncontrast studies. 36 In addition, contrast enhancement provides significant benefits in the detection of alterations in cardiac anatomy. 37 In a study by von der Recke et al, 38 the use of contrast-enhanced TEE confirmed the absence of thrombi in the left atrial appendage in 25 of 41 patients who underwent noncontrast TEE studies with inconclusive results. Contrast enhancement is particularly important in distinguishing the vascular pattern of different types of intracardiac masses, including hypervascular malignant tumors, hypovascular benign stromal tumors, and avascular intracardiac thrombi. 37 Therefore, the combination of the new generation of contrast agents with the development of contrast-targeted imaging modes constitutes powerful and practical tools in the quantitative and qualitative assessment of cardiac structure and function as well as myocardial perfusion.
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Hepatic applications. CEUS imaging also holds promise in enhancing the ability to diagnose and characterize chronic liver disease. Hepatic fibrosis is associated with changes in intrahepatic circulation, including the development of arteriovenous shunts and arterialization of the capillary bed. Such changes could be assessed with CEUS imaging by estimating the intrahepatic transit time of microbubbles and the peak intensity in the hepatic vessels, portal vein, and the liver parenchyma, offering a novel modality for the diagnosis and staging of hepatic fibrosis.
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Contrast enhancement may also be used for screening and early diagnosis of hepatocellular carcinoma, especially in cirrhotic livers where the differentiation between benign regenerative nodules and malignant lesions can be challenging. CEUS imaging is used to characterize microvascular size and volumetric flow of tumor angiogenesis, thereby enhancing tumor detection with ultrasound imaging.
1 Primary and secondary malignant hepatic lesions are associated with angiogenesis and are often dependent on the arterial blood supply rather than the mixed portal/hepatic blood supply seen with nonmalignant tissue. CEUS imaging can demonstrate those vascular changes by showing early enhancement during the arterial phase as well as a "wash-out" in the portal venous and late phases of the examination in some cases. 40, 41 In general, CEUS imaging can provide a sensitive and cost-effective tool for detecting focal liver lesions without exposing the patient to nephrotoxic contrast agents or irradiation. However, dependence on the operator, lack of the 3D dynamic imaging, and the poor acoustic window in some patients remain known limitations for ultrasound examination.
THERAPEUTIC APPLICATIONS
In addition to diagnostic applications, CEUS imaging is currently being studied for therapeutic purposes such as targeted drug delivery into arterial walls and thrombi.
Microbubbles are designed for drug delivery by incorporating oil into the lipid shell, which dissolves hydrophilic or lipophilic drugs that are normally insoluble in an aqueous media. Via ultrasound energy, microbubbles can rapidly change states from relatively stable structures with minimal leak rate to unstable structures with rapid release of contents. To enhance targeting, ligands specific for receptors, such as integrins on endothelial cells, are attached to the microbubble surface. 42 Ultrasound pulses may be used to generate repetitive oscillation of microbubbles, a phenomenon known as cavitation. This results in a pulsing action that creates a jetting flow toward the substrate, generating radial wall shear stress after impact. As a result, adherent cells on the substrate become detached, a process known as sonoporation, thereby increasing porosity and permeability of drugs into tissue or thrombus. 42 In addition, ultrasound creates a pushing force away from the transducer, termed radiation force, which can be used to push microbubbles toward a target tissue, increasing concentration and localization of contrast agents with therapeutic drugs near a vessel wall. 43 One studied application for targeted drug therapy is chemotherapeutic drug delivery, which in theory should concentrate the drug exposure to the local tumor while limiting exposure of healthy tissue to the toxic drugs, thereby minimizing detrimental side effects. 42 Microbubbles containing common anticancer drugs in the hydrophilic core circulate into the tumor microvasculature. At that point, ultrasound pulses are used to burst the microbubbles, releasing the drug and also inducing sonoporation. Subsequent tumor cell death has been demonstrated in vitro and in vivo. 44, 45 In addition, microbubbles can be used for targeted gene delivery; for instance, microbubbles may be loaded with small interfering RNA, which can downregulate transcription factors for cell proliferation, such as signal transducer and activator of transcription 3, thereby decreasing tumor burden. 46 Microbubbles are also being studied for enhancement of sonothrombolysis, a relatively noninvasive method of dissolving thrombus and restoring blood flow using ultrasound energy. The CLOTBUST (Combined Lysis of Thrombus in Brain Ischemia Using Transcranial Ultrasound and Systemic TPA) trial first established the therapeutic benefits of continuous transcranial Doppler for early recanalization in stroke patients. 45 The addition of microbubbles to tissue plasminogen activator treatment (tPA) further increased the rate of recanalization and resulted in higher rates of complete middle cerebral artery recanalization compared with both tPA with transcranial Doppler and tPA alone. 47 Porter et al 48 described similar benefits of microbubbles to fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. The added benefit is likely due to the ultrasound-induced large amplitude microbubble oscillations that cause thrombus deformation. These techniques are especially beneficial when acute percutaneous intervention is not readily available or when thromboembolism involves the distal microvasculature. Microbubble technology is also being studied for potential enhancement of thrombolysis after occlusion of the peripheral vasculature. Tachibana et al 49 are
credited with pioneering the use of microbubbles in sonothrombolysis. In an in vitro study, they were able to demonstrate that insonation of Albunex (Molecular Biosystems Inc, San Diego, Calif) with urokinase led to increased thrombolytic efficacy compared with urokinase alone or urokinase with ultrasound exposure. 49 More recent studies have investigated the application of microbubbles for sonothrombolysis enhancement in vivo. A 2009 study by Alonso et al 50 investigated the potential for targeted abciximab immunobubbles to enhance lysis of human thrombus inserted into rat models. Their results demonstrated that 2-MHz ultrasound combined with abciximab immunobubbles was able to induce thrombolysis without lytic agents that was superior to insonation of nontargeted microbubbles or ultrasound alone. 50 Before these techniques can be adopted into clinical practice, however, further research is necessary to ensure patient safety and develop reliable real-time monitoring protocols.
CONCLUSIONS
The emerging technology of microbubbles and CEUS holds considerable promise for cardiovascular medicine and cancer therapy given its diagnostic and therapeutic utility. Diagnostically, CEUS imaging can better delineate luminal perfusion, identify vessel irregularities, and measure neovascularization as a quantitative indicator of plaque vulnerability and end-muscle perfusion for various vascular pathology. These techniques not only serve as potential future adjuncts to current diagnostic modalities but also may replace current diagnostic paradigms by demonstrating superiority in larger studies. Therapeutically, microbubbles can serve as vehicles of targeted drug and gene therapy delivery. Although many studies have demonstrated numerous benefits and minimal risks of microbubble therapy, more prospective studies with higher sample sizes are needed. Future diagnostic vascular applications of CEUS may include the quantification of neovascularization within AAA and the calculation of time to peak intensity after burst to indirectly measure collateralization in PAD. In terms of future therapeutic applications, CEUS imaging may be used in trials comparing targeted chemotherapy delivery via microbubbles with systemic chemotherapy as well as in trials using microbubble sonothrombolysis for acute ischemic stroke. Overall, with proper training and credentialing of ultrasound technicans, the clinical implications are innumerable as microbubble technology is rapidly bursting onto the scene of cardiovascular medicine. 
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